S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
A gold storm is coming… (Ad)
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
Closing prices for crude oil, gold and other commodities
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Ford, Starbucks fall; Clorox, Gilead Sciences rise
Zimmer Biomet Beats on Earnings, Growth May be Priced In
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
How major US stock indexes fared Friday 2/3/2023
MarketBeat Week in Review – 1/30 - 2/3
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
A gold storm is coming… (Ad)
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
Closing prices for crude oil, gold and other commodities
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Ford, Starbucks fall; Clorox, Gilead Sciences rise
Zimmer Biomet Beats on Earnings, Growth May be Priced In
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
How major US stock indexes fared Friday 2/3/2023
MarketBeat Week in Review – 1/30 - 2/3
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
A gold storm is coming… (Ad)
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
Closing prices for crude oil, gold and other commodities
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Ford, Starbucks fall; Clorox, Gilead Sciences rise
Zimmer Biomet Beats on Earnings, Growth May be Priced In
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
How major US stock indexes fared Friday 2/3/2023
MarketBeat Week in Review – 1/30 - 2/3
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
A gold storm is coming… (Ad)
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
Closing prices for crude oil, gold and other commodities
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Ford, Starbucks fall; Clorox, Gilead Sciences rise
Zimmer Biomet Beats on Earnings, Growth May be Priced In
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
How major US stock indexes fared Friday 2/3/2023
MarketBeat Week in Review – 1/30 - 2/3
NASDAQ:SNOA

Sonoma Pharmaceuticals - SNOA Stock Forecast, Price & News

$1.64
+0.01 (+0.61%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.58
$1.70
50-Day Range
$1.01
$2.02
52-Week Range
$1.00
$4.25
Volume
233,758 shs
Average Volume
5.68 million shs
Market Capitalization
$5.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
SNOA stock logo

About Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock

Sonoma Pharmaceuticals, Inc. engages in developing and producing Stabilized Hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. Its products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Boulder, CO.

Receive SNOA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sonoma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNOA Stock News Headlines

Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Why Is Sonoma Pharmaceuticals (SNOA) Up 70% Today?
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
See More Headlines
Receive SNOA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sonoma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNOA Company Calendar

Last Earnings
11/14/2022
Today
2/04/2023
Next Earnings (Estimated)
2/10/2023
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNOA
Employees
14
Year Founded
1999

Profitability

Net Income
$-5,090,000.00
Pretax Margin
-48.46%

Debt

Sales & Book Value

Annual Sales
$12.63 million
Book Value
$2.81 per share

Miscellaneous

Free Float
2,810,000
Market Cap
$5.08 million
Optionable
Not Optionable
Beta
1.19

Social Links


Key Executives

  • Amy M. Trombly
    Chief Executive Officer & Director
  • Bruce Thornton
    Chief Operating Officer & Secretary
  • Chad White
    Chief Financial Officer













SNOA Stock - Frequently Asked Questions

How have SNOA shares performed in 2023?

Sonoma Pharmaceuticals' stock was trading at $1.12 on January 1st, 2023. Since then, SNOA stock has increased by 46.4% and is now trading at $1.64.
View the best growth stocks for 2023 here
.

When is Sonoma Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 10th 2023.
View our SNOA earnings forecast
.

How were Sonoma Pharmaceuticals' earnings last quarter?

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) released its quarterly earnings results on Monday, November, 14th. The company reported ($0.19) EPS for the quarter. The business earned $3.33 million during the quarter. Sonoma Pharmaceuticals had a negative net margin of 46.28% and a negative trailing twelve-month return on equity of 61.54%.

What other stocks do shareholders of Sonoma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sonoma Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), VelocityShares Daily 2x VIX Short-Term ETN (TVIX), Sorrento Therapeutics (SRNE), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Amarin (AMRN), Pfizer (PFE), Nabriva Therapeutics (NBRV), Verastem (VSTM) and Vaxart (VXRT).

What is Sonoma Pharmaceuticals' stock symbol?

Sonoma Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNOA."

How do I buy shares of Sonoma Pharmaceuticals?

Shares of SNOA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sonoma Pharmaceuticals' stock price today?

One share of SNOA stock can currently be purchased for approximately $1.64.

How much money does Sonoma Pharmaceuticals make?

Sonoma Pharmaceuticals (NASDAQ:SNOA) has a market capitalization of $5.08 million and generates $12.63 million in revenue each year. The company earns $-5,090,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis.

How can I contact Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals' mailing address is 645 MOLLY LANE SUITE 150, WOODSTOCK GA, 30189. The official website for the company is www.sonomapharma.com. The company can be reached via phone at (800) 759-9305, via email at dmcfadden@sonomais.com, or via fax at 707-283-0551.

This page (NASDAQ:SNOA) was last updated on 2/4/2023 by MarketBeat.com Staff